Ingestible TLR Modulator Device for Localized GI Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment regimens for gastrointestinal diseases, such as inflammatory bowel disease, face challenges in delivering therapeutic drugs specifically to the gastrointestinal tract, leading to reduced efficacy and increased side effects due to systemic administration, and existing methods struggle to accurately target and release drugs at specific locations within the GI tract.
Innovation Solution
The development of ingestible devices equipped with a pharmaceutical formulation containing a TLR modulator, which includes a housing, a reservoir, and a release mechanism, allowing for controlled and localized release of the therapeutic agent proximate to disease sites within the GI tract, utilizing sensors and actuators to trigger the release based on predetermined locations or disease detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If therapeutic drugs are administered orally for systemic distribution, then the treatment covers the entire body, but the drug is contaminated and digested in the stomach, reducing efficacy at the target site and increasing systemic side effects
Solution Approach 1:
The patent segments the gastrointestinal tract into distinct regions (stomach, small intestine, large intestine) and uses location-specific drug delivery devices that release drugs at predetermined target sites rather than systemic distribution. This segmentation allows the drug to bypass stomach degradation and deliver therapeutic agents directly to the intended location, resolving the contradiction between comprehensive coverage and target-site efficacy.
Solution Approach 2:
The patent introduces ingestible devices as intermediary carriers that protect the drug from stomach contamination and digestion. These devices serve as mediators between the oral administration route and the target site in the gastrointestinal tract, enabling the drug to survive the harsh stomach environment and reach the target site intact, thereby resolving the contradiction between oral accessibility and drug protection.
2Measurement precision
If a device is used to transport and deliver drug to a specific location in the GI tract, then the drug can be delivered precisely to the target site, but the device complexity increases and safe operation becomes more difficult
Solution Approach 1:
The patent designs ingestible devices with multiple functions integrated into a single system: location detection, drug delivery, and sometimes diagnostic capabilities. These multi-functional devices can target specific locations in the GI tract while maintaining relatively simple structures that can be swallowed and operated safely. The universal design resolves the contradiction by combining precision delivery capabilities with user-friendly operation.
Solution Approach 2:
The patent employs ingestible devices that autonomously navigate to predetermined target sites in the GI tract and automatically release drugs without requiring complex external control mechanisms. The devices self-regulate their operation based on location detection, eliminating the need for complex manual operation or sophisticated control systems, thereby achieving precise drug delivery with simplified device operation.
3Quantity of substance
If therapeutic drugs are administered systemically, then the treatment reaches all areas of the body, but the bioavailability at the target site is reduced and systemic toxicity increases
Solution Approach 1:
The patent implements local quality by delivering drugs directly to specific locations in the gastrointestinal tract rather than distributing them systemically throughout the body. This localized delivery approach concentrates the therapeutic agent at the target site, achieving high drug concentration where needed while minimizing exposure to other body systems, thereby resolving the contradiction between target-site efficacy and systemic toxicity.
Solution Approach 2:
The patent extracts the drug delivery function from the systemic circulation pathway and redirects it through a localized gastrointestinal route. By taking the drug out of the systemic distribution system and delivering it directly to the GI tract target site, the patent achieves high local concentration while avoiding the harmful effects of systemic exposure, resolving the contradiction between bioavailability and toxicity.
Data Source
AI summary
This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TLR agonist.